Xpovio Tablet, Film Coated
NDC Package 72237-101-04
Package Information
Xpovio (selinexor) tablets is a medication used to treat cancer. This formulation utilizes a tablet, film coated delivery system. Marketed by Karyopharm Therapeutics Inc., this product is identified by NDC 72237-101 and is authorized under FDA application NDA212306.
Identification & Billing
- RxCUI: 2178395 - selinexor 20 MG Oral Tablet
- RxCUI: 2178402 - XPOVIO 20 MG Oral Tablet
- RxCUI: 2178402 - selinexor 20 MG Oral Tablet [Xpovio]
- RxCUI: 2178402 - Xpovio 20 MG Oral Tablet
- RxCUI: 2178406 - {32 (selinexor 20 MG Oral Tablet) } Pack
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72237 - Karyopharm Therapeutics Inc.
- 72237-101 - Xpovio
- 72237-101-04 - 4 BLISTER PACK in 1 CARTON / 8 TABLET, FILM COATED in 1 BLISTER PACK (72237-101-14)
- 72237-101 - Xpovio
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72237-101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72237-101-04 identifies a specific commercial package of 4 blister pack in 1 carton / 8 tablet, film coated in 1 blister pack (72237-101-14) of Xpovio, a human prescription drug labeled by Karyopharm Therapeutics Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 4 billable units per package. This tablet, film coated is formulated for oral use and contains selinexor as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Karyopharm Therapeutics Inc. on July 10, 2019. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat cancer. Selinexor works by slowing or stopping the growth of cancer cells.
How is this Karyopharm Therapeutics Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72237010104. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 4 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.